Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gary D. Glick
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 1.43
- Country
- US
Financials
ODTX has only 2 quarterly periods on file — the charts below show the full history available.
Net Income
$-52.79MEBITDA
$-51.73MFree Cash Flow
$-34.69MEPS (diluted)
$-1.74Shares Outstanding (diluted)
30.28M-35.8%Operating Expenses
$46.74MCash & Debt
$310.57MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.98M | $-148.65M | $-5.39 |
Valuation
ODTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+128.57%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·6h ago·Positive
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
View source ↗ - Newsglobenewswire.com·14h ago·Neutral
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
…ce call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that additional results from the OD-001 induction period of its Pha…
View source ↗ - Newsglobenewswire.com·34d ago·Positive
…y Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the…
View source ↗
Earnings
Wed, Nov 4(in 2 weeks)
Consensus estimate $-1.07 per share
Typical surprise -258.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.74 vs $-1.61miss
- Wed, Jun 17$-6.77 vs $-1.11miss
Estimates and results for ODTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ODTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.